https://www.avient.com/sites/default/files/2021-04/avient-q4-earnings-and-2021-outlook-website.pdf
D
is
t.
)
R
P
M
P
P
G
K
W
R
F
U
L
A
V
Y
G
C
P
IF
F
F
M
C
H
X
L
H
U
N
E
M
N
F
O
E
E
C
L
K
R
A
S
C
L
A
S
H
C
E
G
R
A
A
L
B
Median: 5%Median: 3%
Source: Peer data per Bloomberg market data as of February 5, 2021
Avient reflects 2021 estimated revenue of $4,100M and excludes one-time synergy capture CAPEX ($20M)
Avient Specialty
Formulators
Other
Chemical/Specialty
Companies
Free Cash Flow Conversion (1)
2021E (%)
Being asset light helps us to generate
strong free cash flow that is in line
with specialty formulators.
Free cash flow conversion calculated as (EBITDA – Capex) / EBITDA
Median: 83% Median: 76%
H I G H F R E E C A S H F L OW
C O N V E R S I O N
Avient reflects 2021 estimated EBITDA of $510M and excludes one-time synergy capture CAPEX ($20M)
Source: Peer data per Bloomberg market data as of February 5, 2021
85 87 86 86
81 81
59
92
88
81 79 79 79
76 76 75
73
67 67
64
60
7
A
vi
e
n
t
P
P
G
K
W
R
R
P
M
F
U
L
A
V
Y
G
C
P
IF
F
F
M
C
U
N
V
R
H
X
L
E
M
N
B
N
R
E
C
L
C
E
A
S
H
F
O
E
G
R
A
H
U
N
K
R
A
S
C
L
A
L
B
Source: Peer data per Bloomberg market data as of February 5, 2021
Total Enterprise Value / 2021E EBITDA
Our current valuation implies an
EBITDA multiple that is significantly
below specialty formulator peers and
our historic valuations, when the
company had considerable exposure
to more cyclical and challenging end
markets.
Reconciliation of Non-GAAP Financial Measures
(Unaudited)
(Dollars in millions, except for per share data)
Senior management uses comparisons of adjusted net income from continuing operations attributable to Avient shareholders
and diluted adjusted earnings per share (EPS) from continuing operations attributable to Avient shareholders, excluding special
items, to assess performance and facilitate comparability of results.
https://www.avient.com/sites/default/files/2021-12/AVNT 2021 Investor Day_0.pdf
D
is
t.
)
K
W
R
P
P
G
A
V
Y
F
U
L
R
P
M
G
C
P
F
M
C
H
X
L
H
U
N
E
C
L
E
M
N
C
E
A
S
H
S
C
L
Source: Peer data per Bloomberg market data as of December 2, 2021
Avient reflects 2021 estimated revenue of $4,750M and estimated CAPEX of $80M (excludes one-time synergy capture CAPEX of $20M)
129Avient Corporation
474
644
1,002
107
147
216
467
616
872
2014 2018 2021E
R&D / Technical Marketing Sales
Commercial Resources
Headcount figures all Pro Forma for sale of Designed Structures and Solutions (DSS) and Performance Products and Solutions (PP&S) segments.
2021E data as of October 31, 2021.
Peer data per Bloomberg market data as of December 2, 2021.
We expect this
expansion to continue as we execute
our strategy, increase margins and
consistently grow earnings in excess
of the market.
6.5
9.0
11.2
17.7
16.7
15.5 15.3
14.5
12.2
25.7 25.5
13.5
12.2
10.7
9.8
8.6 8.5
6.9
6.2
A
vi
e
n
t
(2
0
1
1
)
A
vi
e
n
t
(2
0
1
6
)
A
vi
e
n
t
(2
0
2
1
)
K
W
R
P
P
G
A
V
Y
R
P
M
G
C
P
F
U
L
H
X
L
E
C
L
A
S
H
F
M
C
B
N
R
S
C
L
E
M
N
U
N
V
R
C
E
H
U
N
Source: Peer data per Bloomberg market data as of December 2, 2021
Total Enterprise Value / 2021E EBITDA
Avient 2011 and 2016 valuations reflect trailing 12 months EBITDA at December 31 of the respective years.
https://www.avient.com/sites/default/files/2022-08/Avient CDP_Climate_Change_Questionnaire_2022.pdf
C0.2
(C0.2) State the start and end date of the year for which you are reporting data.
Upstream leased assets
Evaluation status
Relevant, calculated
Emissions in reporting year (metric tons CO2e)
670
Emissions calculation methodology
Average data method
Percentage of emissions calculated using data obtained from suppliers or
value chain partners
100
Please explain
Upstream leased assets data includes mileage data from leased vehicles provided by
our leasing agencies of choice.
Polymers 45 Purchased polymers data, broken out by polymer type,
was obtained in weight.
https://www.avient.com/sites/default/files/2022-05/AVNT May IR Presentation w Non GAAP Recs.pdf
Whether
an additional line at an existing
manufacturing plant, or a new
facility in a growing region, we
ramp-up quickly and cost-efficiently.
43
Capex / Revenue
2022E (%)
AV I E N T I S A S S E T L I G H T
Avient Specialty
Formulators
Other
Chemical/Specialty
Companies
2
3
2 2
2
3
4
3 3
5
5
7 7
8
11
A
vi
en
t
A
vi
en
t P
F
F
U
L
K
W
R
P
P
G
R
P
M
A
V
Y
F
M
C
H
U
N
H
X
L
E
C
L
E
M
N
C
E
A
S
H
S
C
L
Source: Peer data per Bloomberg market data as of April 21, 2022.
Source: Peer data per Bloomberg market data as of April 21, 2022
86
82
86 86 84
78 77
89 86
81 80
76 76 76
67 67
11
(12)
A
vi
en
t
A
vi
en
t P
F
F
U
L
K
W
R
P
P
G
R
P
M
A
V
Y
F
M
C
U
N
V
R
B
N
R
H
U
N
H
X
L
E
C
L
C
E
A
S
H
E
M
N
S
C
L
A
LB
12%
18%
16% 15% 15% 14% 14%
28% 28%
26%
25%
22% 21% 19%
16%
12%
9% 9%
A
vi
en
t T
od
ay
A
vi
en
t P
F
A
V
Y
P
P
G
K
W
R
FU
L
R
P
M C
E
A
LB
FM
C
A
S
H
E
C
L
E
M
N
H
X
L
H
U
N
S
C
L
B
N
R
U
N
V
R
Median: 21%Median: 15%
2 0 2 2 E B I T DA M A RG I N S V S .
Financials are pro forma for the acquisition of Dyneema® and potential divestiture of Distribution
Avient Specialty
Formulators
Other Specialty /
Chemical Companies
45
Source: Peer data per Bloomberg market data as of April 21, 2022
Total Enterprise Value / NTM EBITDA
With the Dyneema and Clariant
Color business acquisition and
divestment of the PP&S business,
along with the proposed sale of
our Distribution business, our
exposure is now concentrated in
less-cyclical and high-growth
markets.
https://www.avient.com/sites/default/files/2024-08/PCF One-pager.pdf
This certification
ensures that our tool meets rigorous criteria and
addresses relevant safety aspects, providing you
with reliable and accurate data.
https://www.avient.com/sites/default/files/2022-10/Cesa WithStand Patient Mobility Case Study %281%29.pdf
Avient has compiled extensive data
that enabled the OEM to shave weeks off the product
development timeline and save nearly $50,000 in
potential antimicrobial product protection testing fees.
https://www.avient.com/sites/default/files/2021-06/fl.datasheet-twisting.pdf
Uranusweg 3
8938 AJ Leeuwarden
The Netherlands
+31(0) 58 216 75 99
info@fiber-line.com
ABOUT FIBER-LINE®
NOTICE: The information and data contained herein do not constitute sales specifications.
https://www.avient.com/sites/default/files/2024-10/Avient_CodeConduct_2024_final2.pdf
This includes how you collect, use,
store, share, and preserve or delete or dispose of personal
data.
Details are covered in the Global Privacy and
Data Protection Policy available on The Loop, under People &
Departments, Ethics & Corporate Policies.
You must familiarize yourself and comply with
company policies, procedures and protocols on security,
information management, and cybersecurity, including but
not limited to those contained in Avient’s Information
Systems Use Policy, Global Privacy and Data
Protection Policy and Cyber and Data Incident
Response Policy.
https://www.avient.com/sites/default/files/2023-11/AVNT November IR Presentation.pdf
PRIOR YEAR
$790
$710
2022 2023
$107
$112
2022 2023
Sales Adjusted EBITDA
(in millions)
$0.42
$0.47
2022 PF 2023
Adjusted EPS
(in millions)
- 10% + 5% + 12%
Sales Adjusted EBITDA Adjusted EPS
16
$112
$500
Q4 FY
$0.47
$2.30
Q4 FY
Q4 AND FULL YEAR 2023 GUIDANCE
$710
$3,130
Q4 FY
Sales Adjusted EBITDA Adjusted EPS
17
(in millions) (in millions)
Guidance: Free Cash Flow
$180 $180
Prior Guidance Guidance
FREE CASH FLOW & INCREASED DIVIDEND
13th Consecutive Dividend Increase
0.16
0.26
0.42
0.58
0.79
0.85
0.99
1.03
2011 2013 2015 2017 2019 2021 2023 2024
18
S U S T A I N A B I L I T Y D AY
R E C A P
SUSTAINABILITY AS A GROWTH DRIVERLONG-TERM REVENUE GROWTH DRIVERS
60%+
Key Growth
Drivers
Sustainable
Solutions
Composites, Healthcare,
Asia / LATAM
Overlap
Other
(GDP Growth)
Total Company Revenue
Growth Drivers Long-Term Growth Rate
Sustainable Solutions 8–12%
Composites 8–10%
Healthcare 8–10%
Asia / LATAM 5%
Other (GDP growth) 0–2%
Avient 6%
20
SUSTAINABILITY TRENDS DRIVE LONG-TERM GROWTH
8-12%
Long Term
Growth
50
90
2022 2030
Medical Plastics
Market Size
(in $Billions)
2020 2030
Recycled
Plastics
Virgin
Plastics
Growing Demand
for Recycled
Content
Avient Sustainable
Solutions
18
46
2023 2032
Global Offshore Annual
Wind Installations
(in Gigawatts)
Sources: McKinsey, Bloomberg, Grand View Research
SUSTAINABILITY TRENDS DRIVE
LONG-TERM GROWTH
21
• Transformative acquisitions
combined with divestitures of
more cyclical businesses have
improved margins over 400 bps
since 2018
• 20% long-term margin goal to
be driven by key growth drivers,
with sustainable solutions
playing a meaningful role
5.4%
11.5%
16.0%
2006 2018 2023E Recovery Growth
Drivers
Strategic
Objective
20%+
+1%+
+3%+
ADJUSTED EBITDA MARGIN EXPANSION
22
• 6% annualized long-term sales growth leveraging
sustainable solutions, composites, healthcare, and
emerging regions
• Expand EBITDA margins to 20%
• Deliver annual EBITDA and EPS growth of
10% and 15%
• Maintain asset-light, 80% free cash flow conversion
profile and be valued as a specialty formulator
• Continue fostering our Great Place to Work® culture
CRE AT ING A WORL D-CL AS S
S US TAINABL E ORGANIZ AT ION
23
PEER COMPARISONS
AVIENT IS ASSET LIGHT
Capex / Revenue
2023E (%)
Avient Specialty
Formulators
Other Specialty /
Chemical Companies
Source: Peer data per Bloomberg as of October 27, 2023
Note: Avient reflects 2023 estimated revenue of $3,130 and estimated run-rate CAPEX of $110M.
26
3.5
1.8
2.7 3.0
3.4 3.7
2.8
3.7
4.6 5.0
6.9 7.0
8.6
11.1
A
vi
en
t
K
W
R
FU
L
P
P
G
A
V
Y
R
P
M
FM
C
H
U
N
C
E
E
C
L
A
S
H
H
X
L
E
M
N
S
C
L
FREE CASH FLOW CONVERSION
Source: Peer data per Bloomberg as of October 27, 2023
Note: Free cash flow conversion calculated as (Adjusted EBITDA – Capex) / Adjusted EBITDA.
Avient reflects 2023 adjusted EBITDA guidance of $500M and estimated run-rate CAPEX of $110M.
2023E (%)
27
78
89
84 82 80 77
88
81
76
70 69
60
54
(6)
A
vi
en
t
K
W
R
FU
L
P
P
G
A
V
Y
R
P
M
FM
C
C
E
E
C
L
A
S
H
H
X
L
H
U
N
E
M
N
S
C
L
Avient Specialty
Formulators
Other Specialty /
Chemical Companies
MULTIPLE EXPANSION
Source: Peer data per Bloomberg as of October 27, 2023
Note: Avient reflects 2023 adjusted EBITDA guidance of $500M and closing share price of $31.18.
Avient 2011, 2018 and 2021 multiples reflect trailing 12 months EBITDA at December 31.
28
EV / 2023E EBITDA
6.5
8.5
11.0
8.9
12.0 11.9
10.9
9.9
8.2
16.3
13.8
11.9
9.6 9.5 9.5 9.2
7.7
20
11
20
18
20
21
O
ct
20
23
A
V
Y
R
P
M
P
P
G
K
W
R
FU
L
E
C
L
H
X
L
S
C
L
A
S
H
FM
C
C
E
H
U
N
E
M
N
Avient Historic Multiple
Avient Specialty
Formulators
Other Specialty /
Chemical Companies
A P P E N D I X
30
Performance
Additives
16%
Pigments
12%
TiO2
10%
Dyestuffs
2%
Polyethylene
11%
Nylon
6%
Polypropylene
5%
Styrenic Block
Copolymer
5%
Other Raw
Materials
33%
~40% hydrocarbon based
(Grey shaded materials are hydrocarbon based,
includes portion of “Other Raw Materials”)
Non-hydrocarbon
based materials
2022 pro forma results for the acquisition of Avient Protective Materials
RA W MATERIAL BASKET
SEGMENT DATA
U.S. & Canada
40%
EMEA
37%
Asia
18%
Latin America
5%
2022 PRO FORMA SEGMENT, END MARKET AND GEOGRAPHY
GEOGRAPHY REVENUESEGMENT FINANCIALS
Consumer
20%
Packaging
24%
Industrial
15%
Building and
Construction
10%
Telecommunications
4%
Energy
4%
Defense
6%
END MARKET REVENUE
$2,355M $402M
$1,300M $272M
Sales EBITDA
Specialty Engineered Materials
Color Additives and Inks
$592M$3,653M
(1)
Transportation
9%
Healthcare
8%
32
(1) Total company sales and adjusted EBITDA of $3,653M and $592M, respectively, include intercompany sales eliminations and corporate costs
2 0 2 2 R E V E N U E | $ 2 . 4 B I L L I O N
US & Canada
34%
EMEA
38%
Asia
20%
Latin America
8%
END MARKET REGION
33
Packaging
34%
Consumer
21%
Healthcare
8%
Industrial
15%
Transportation
8%
Building &
Construction
11%
Telecommunications
1% Energy
2%
COLOR, ADDITIVES & INKS
2 0 2 2 P R O F O R M A R E V E N U E | $ 1 . 3 B I L L I O N
US & Canada
52%
EMEA
35%
Asia
13%
34
Packaging
5%
Consumer
19%
Healthcare
8%Industrial
16%
Transportation
10%
Telecommunications
10%
Energy
9% Defense
15%
Building &
Construction
8%
END MARKET REGION
SPECIALTY ENGINEERED MATERIALS
Packaging
32%
Consumer
27%
Healthcare
8%
Industrial
14%
Building &
Construction
5%
Telecommunications
3%
Energy
1% Defense
1%
Asia
(18% of sales)
Transportation
9%
2 0 2 2 P R O F O R M A AV I E N T R E G I O N A L S A L E S
Packaging
27%
Consumer
14%
Healthcare
5%
Industrial
17%
Building &
Construction
10%
Energy
5%
Defense
8%
EMEA
(37% of sales)Transportation
11%
Packaging
13%
Consumer
24%
Healthcare
12%
Industrial
15%
Building &
Construction
13%
Energy
5%
Defense
5%
US &
Canada
(40% of sales)
Transportation
7%
Packaging
56%
Consumer
23%
Healthcare
4%
Industrial
7%
Building &
Construction
4%
Telecommunications
1%
LATAM
(5% of sales)
Transportation
5%
Telecommunications
3%
Telecommunications
6%
35
B Y E N D M A R K E T
Reconciliation of Non-GAAP Financial Measures
(Unaudited)
(Dollars in millions, except for per share data)
Senior management uses comparisons of adjusted net income from continuing operations attributable to Avient shareholders
and diluted adjusted earnings per share (EPS) from continuing operations attributable to Avient shareholders, excluding special
items, to assess performance and facilitate comparability of results.
https://www.avient.com/sites/default/files/2023-03/AVNT Mar 2023 Earnings Presentation.pdf
Additionally, Adjusted EPS excludes the impact of special items and amortization expense
associated with intangible assets.2
AVI ENT: WHO WE A RE
36
24
9
35
• U.S. and Canada
• Latin America
• Europe, Middle East & Africa
• Asia
25,000+
CUSTOMERS
Headquartered in Avon Lake, OH
(Cleveland)
100+ manufacturing plants
Key Financial Data
2023E Sales $3.45 billion
2023E EBITDA $530 million
2023E EPS $2.40
100%
ARE CUSTOMIZED SOLUTIONS
TO UNIQUE SPECIFICATIONS
of
sales
3
Guidance as of February 15, 2023 Webcast
W H O W E A R E – V I S I O N , S T R AT E G Y, C U LT U R E
4
Avient Corporation (NYSE: AVNT) provides
specialized and sustainable material solutions that
transform customer challenges into opportunities,
bringing new products to life for a better world.
$600 $592
2021 2022
$3.02 $3.04
2021 2022
FULL YEAR 2022 PERFORMANCE
( T O TA L C O M PA N Y P R O F O R M A )
19
Sales Adjusted EBITDA
$3,712 $3,653
2021 2022
- 2%
Adjusted EPS
- 1% + 1%
(in millions) (in millions)
(+ 4% excluding FX) (+ 5% excluding FX) (+ 9% excluding FX)
FULL YEAR 2022 SEGMENT PERFORMANCE
20
CAI
$2,402 $2,355
Sales
($ in millions)
$409 $402
EBITDA
SEM Pro Forma
$1,308 $1,300
Sales
$278 $272
EBITDA
(+ 4% excluding FX)
- 2% - 1%
(+ 5% excluding FX)
- 2%
(+ 4% excluding FX)
- 2%
(+ 2% excluding FX)
PRO FORMA FULL YEAR EPS BRIDGE
21
Pro Forma 2021 Adjusted EPS 3.02$
Foreign Currency (0.23)
Russia Import Sales (0.07)
Outdoor High Performance (0.13)
Color, Additives and Inks 0.18
Specialty Engineered Materials 0.24
Corporate Costs / Other 0.03
Pro Forma 2022 Adjusted EPS 3.04$
FULL YEAR EBITDA BRIDGE
( P R O F O R M A T O TA L C O M PA N Y )
22
$ millions
CAI:
Price / Mix 247
Inflation (176)
SEM:
Price / Mix 121
Inflation (77)
Net Price Benefit 115
Wage and Energy Inflation (47)
Clariant Color Integration Synergies 23
Incentives, Other Employee Costs 43
FX (34)
Full Year 2022 $592
Adjusted
EBITDA
Full Year 2021 $ 600
Demand (99)
Russia Import Sales (9) • Demand primarily impacted
by China lockdowns, 4th
quarter industrywide
destocking and declining
consumer sentiment
• Pricing outpaced inflation of
raw materials, wages and
energy
2 0 2 3 G U I D A N C E
$125
$530
Q1 FY
$0.55
$2.40
Q1 FY
2023 GUIDANCE
24
Sales Adjusted EBITDA
$845
$3,450
Q1 FY
Adjusted EPS
(in millions) (in millions)
CA SH FLOW / BALANCE SHEET
25
• IT investment to further
integrate acquired
businesses and capture
operational efficiencies
• Restructuring actions to
streamline operations and
improve profitability, primarily
in Europe
($ millions) 2023E
Cash Flow from Operating Activities 350$
Less:
Run-Rate CapEx (110)
CapEx for IT System Upgrade (25)
CapEx for Restructuring (15)
Total CapEx (150)
Free Cash Flow 200$
Adjusted EBITDA 530$
Net Debt / Adjusted EBITDA 2.9x
K E Y G R O W T H D R I V E R S
A N D T R A N S F O R M E D
P O R T F O L I O
GROW TH DR IVER S: PROV EN SUCC ESS
27 (1) Pro forma for the acquisition of Avient Protective Materials (APM)
COMPOSITES
$51
$84
$212
$668
2016 2018 2020 2022
Long Term Growth Rate
10%
Organic CAGR
10%
HEALTHCARE
$108 $113
$231
$293
2016 2018 2020 2022
Long Term Growth Rate
8-10%
Organic CAGR
11%
ASIA/EMERGING REGIONS
$265
$358
$726
$830
2016 2018 2020 2022
Long Term Growth Rate
5%
Organic CAGR
12%
$340
$455
$790
2016 2018 2020 2022
$1,175
SUSTAINABLE SOLUTIONS
Long Term Growth Rate
8-12%
Organic CAGR
11%
(1) (1)(1)
(Sales in $ millions)
#1 Color Formulator
Dyneema® - World’s Strongest
Fiber™
#1 in Composites applications
for outdoor high performance
#1 in Performance Inks
Customized solutions
140+ PhDs on staff
Rapid development of
innovative products
Extensive patent (2,500+)
portfolio
33% Vitality Index
Better-positioned toward stable,
high-growth end markets
Consumer, packaging,
healthcare and defense comprise
nearly 60% of sales
Agnostic to raw materials,
helping all customers achieve their
goals
Broad portfolio of diversified
sustainable solutions
90%+ of our innovation pipeline
invested in sustainable solutions
Long-term growth rate well
above GDP with expectations of
8-12%
L E V E R AG I N G O U R T R A N S F OR M E D PO RT F O L I O
28
Healthcare
8%
Packaging
24%
Consumer
20%
Building &
Construction
10%
Industrial
15%
Transportation
9%
Energy
4% Telecom.
4%
2022 PF
$3.65B
sales
Defense
6%
Leading Positions Sustainable SolutionsDiversified IndustriesSpecialty Formulator
(1) 2022 Pro forma for the acquisition of Avient Protective Materials
(2) 2020 Pro forma for the acquisition of Clariant Color
(1)(2)
(1)
$340M
$455M
$790M
2016 2018 2020PF 2022PF
$1,175M
P E E R C O M PA R I S O N S
AV I E N T I S A S SE T L I G H T
Capex / Revenue
2023E (%)
Avient Specialty
Formulators
Other Specialty /
Chemical Companies
Source: Peer data per Bloomberg as of February 13, 2023
Note: Avient reflects 2023 estimated revenue of $3,450 and estimated run-rate CAPEX of $110M.
30
3
2
3
3
4 4
3
4
5 5 5
6
7 7
A
vi
e
n
t
K
W
R
P
P
G
F
U
L
A
V
Y
R
P
M
F
M
C
H
U
N
H
X
L
C
E
E
C
L
A
S
H
S
C
L
E
M
N
F R E E C A S H F LOW C O N V E R S I O N
Source: Peer data per Bloomberg as of February 13, 2023
Note: Free cash flow conversion calculated as (Adjusted EBITDA – Capex) / Adjusted EBITDA.
Avient Specialty
Formulators
Other Specialty /
Chemical Companies
2023E(%)
31
79
87
81 79
76
73
90
77 76 75 73
64
59
33
A
vi
e
n
t
K
W
R
P
P
G
F
U
L
A
V
Y
R
P
M
F
M
C
C
E
A
S
H
H
X
L
E
C
L
H
U
N
E
M
N
S
C
L
M U LT I P L E E X PA N S I O N
Avient Specialty
Formulators
Other Specialty /
Chemical Companies
Source: Peer data per Bloomberg as of February 13, 2023
Note: Avient reflects 2023 adjusted EBITDA guidance of $530M and closing share price of $38.89.